Table 3.
Clinical Characteristics of Relapses
| Relapses | Pediatric | Adult | ||
| Ab-positive, n = 29 | Ab-negative, n = 0 | Ab-positive, n = 52 | Ab-negative, n = 15 | |
| No. of patients with any relapse, n (%) | 9 (31) | 0 (0) | 22 (40) | 3 (20) |
| NMDA | 5/22 (23) | 6/20 (30) | ||
| AMPA | 1/1 (100) | 1/2 (50) | ||
| GAD65 | 1/4 (25) | 3/5 (60) | ||
| VGKC | 1/1 (100) | 3/4 (75) | ||
| TPO | 2/3 (67) | 1/9 (11) | ||
| AchR | — | 1/3 (33) | ||
| Amphiphysin | — | 1/1 (100) | ||
| ANNA2 | — | 2/2 (100) | ||
| CASPR2 | — | 2/4 (50) | ||
| LGI1 | — | 5/8 (63) | ||
| CRMP5 | — | 1/2 (50) | ||
| GABA | — | 0/1 (0) | ||
| GFAP | — | 0/2 (0) | ||
| Glycine | — | 1/1 (100) | ||
| Hu | — | 1/2 (50) | ||
| Yo | — | 1/3 (33) | ||
| Time to first relapse, mo (mean ± SD) | 10.6 ± 7.4 | — | 13.1 ± 24.5 | 6.9 ± 3.8 |
Abbreviations: AchR = acetylcholine receptor; AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANNA2 (Ri):antineuronal nuclear autoantibody type 2; CRMP5 = CV2/collapsing response mediator protein; GABA = gamma-aminobutyric acid; GAD65 = glutamic acid decarboxylase 65; GFAP = glial fibrillary acidic protein; Hu/ANNA1 = antineuronal nuclear autoantibody type 1; LGI1 = leucine-rich glioma-inactivated 1; TPO = thyroid peroxidase; VGKC = voltage-gated potassium channel; Yo = Purkinje cell cytoplasmic antibody type 1.